L-MIND study, MOR208 + lenalidomide in R/R DLBCL
Gilles Salles | ASH 2018 | MOR208 combined with lenalidomide in patients with R/R DLBCL
Gilles Salles discusses MOR208 combined with lenalidomide in patients with R/R DLBCL at ASH 2018
Tafasitamab plus lenalidomide granted priority review by US FDA
A BLA submitted for tafasitamab (MOR208), in combination with lenalidomide, will be given Priority Review FDA for R/R DLBCL.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month